Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | ROS1 | P08922 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27408521 | 0.85 | KDM4E (0.49) | ADORA3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL23089432 | 0.81 | ABL1 (0.54) | ADORA3NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL29814852 | 0.81 | ABL1 (0.54) | ADORA3NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL19657732 | 0.80 | LCK (0.41) | ADORA3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL13727358 | 0.79 | LCK (0.46) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17963905 | 0.75 | SORT1 (0.33) | ADORA3SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL18103921 | 0.75 | ALDH1A1 (0.37) | ADORA3RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1424927 | 0.74 | LMNA (0.51) | KDM4EALDH1A1MAPTRECQL | |
| SCHEMBL1424963 | 0.73 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23885090 | 0.73 | CFD (0.42) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4067347-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20220041588-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2022-02-10 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3464270-A2 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205536-A2 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041588-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ABL1, ERBB2 | ADORA3 1408/4885NPC1 3649/4885RAB9A 901/4885 |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | ADORA3 3503/4885NPC1 548/4885RAB9A 2455/4885 |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | ADORA3 3560/4885NPC1 504/4885RAB9A 2590/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | ADORA3 3560/4885NPC1 504/4885RAB9A 2590/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | ADORA3 3560/4885NPC1 504/4885RAB9A 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.